| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
|
Gastroenterology
|
2007
|
5.75
|
|
2
|
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.
|
Liver Transpl
|
2005
|
2.43
|
|
3
|
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.
|
Proc Natl Acad Sci U S A
|
2011
|
2.17
|
|
4
|
Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis.
|
J Hepatol
|
2010
|
1.97
|
|
5
|
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2.
|
Hepatology
|
2010
|
1.88
|
|
6
|
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2.
|
Gastroenterology
|
2010
|
1.85
|
|
7
|
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
|
Hepatology
|
2004
|
1.83
|
|
8
|
Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases.
|
Ann Surg
|
2004
|
1.79
|
|
9
|
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
|
Cancer Res
|
2006
|
1.76
|
|
10
|
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.
|
J Clin Oncol
|
2002
|
1.75
|
|
11
|
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
|
Cancer Res
|
2005
|
1.73
|
|
12
|
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma.
|
Liver Int
|
2011
|
1.60
|
|
13
|
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
|
Hepatology
|
2012
|
1.55
|
|
14
|
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study.
|
Surgery
|
2005
|
1.54
|
|
15
|
AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.
|
Cancer Res
|
2012
|
1.52
|
|
16
|
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
|
Gastroenterology
|
2010
|
1.52
|
|
17
|
Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression.
|
Ann Surg
|
2003
|
1.48
|
|
18
|
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma.
|
Arch Surg
|
2005
|
1.44
|
|
19
|
Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation.
|
Liver Transpl
|
2003
|
1.44
|
|
20
|
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.
|
Proc Natl Acad Sci U S A
|
2005
|
1.40
|
|
21
|
HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing.
|
Oncogene
|
2005
|
1.34
|
|
22
|
Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion.
|
Hepatology
|
2009
|
1.34
|
|
23
|
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification.
|
Ann Surg
|
2003
|
1.27
|
|
24
|
Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma.
|
Int J Cancer
|
2003
|
1.24
|
|
25
|
Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
|
Hepatology
|
2007
|
1.18
|
|
26
|
Hepatic resection for combined hepatocellular and cholangiocarcinoma.
|
Arch Surg
|
2003
|
1.17
|
|
27
|
P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
|
Cancer Res
|
2007
|
1.17
|
|
28
|
Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance.
|
Hepatology
|
2011
|
1.15
|
|
29
|
Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis.
|
Hepatology
|
2012
|
1.13
|
|
30
|
Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.
|
Cancer Chemother Pharmacol
|
2002
|
1.11
|
|
31
|
Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection.
|
PLoS One
|
2011
|
1.11
|
|
32
|
Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.
|
J Hepatol
|
2003
|
1.10
|
|
33
|
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
|
Hepatology
|
2014
|
1.08
|
|
34
|
Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b.
|
Hepatology
|
2012
|
1.06
|
|
35
|
Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
|
PLoS One
|
2009
|
1.05
|
|
36
|
Liver transplantation for combined hepatocellular cholangiocarcinoma.
|
Asian J Surg
|
2007
|
1.04
|
|
37
|
Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis.
|
J Pathol
|
2012
|
1.03
|
|
38
|
Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis.
|
Cancer Res
|
2011
|
1.02
|
|
39
|
High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
|
Hum Pathol
|
2004
|
1.01
|
|
40
|
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
|
Clin Cancer Res
|
2004
|
1.01
|
|
41
|
High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation.
|
Cancer
|
2002
|
1.01
|
|
42
|
Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma.
|
Hepatology
|
2006
|
1.00
|
|
43
|
Mitochondrial targeting of growth suppressor protein DLC2 through the START domain.
|
FEBS Lett
|
2005
|
1.00
|
|
44
|
Regulation of hepatocarcinogenesis by microRNAs.
|
Front Biosci (Elite Ed)
|
2013
|
1.00
|
|
45
|
Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population.
|
PLoS One
|
2011
|
0.99
|
|
46
|
Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B.
|
Am J Gastroenterol
|
2004
|
0.99
|
|
47
|
Hepatic resection for bilobar hepatocellular carcinoma: is it justified?
|
Arch Surg
|
2003
|
0.98
|
|
48
|
RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.
|
Hepatology
|
2013
|
0.98
|
|
49
|
Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
|
J Natl Cancer Inst
|
2012
|
0.98
|
|
50
|
Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma.
|
Clin Cancer Res
|
2006
|
0.94
|
|
51
|
Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
|
Liver Int
|
2009
|
0.93
|
|
52
|
Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion.
|
PLoS One
|
2012
|
0.92
|
|
53
|
Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma.
|
J Gastrointest Surg
|
2004
|
0.92
|
|
54
|
Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway.
|
Carcinogenesis
|
2003
|
0.91
|
|
55
|
RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it.
|
Liver Int
|
2010
|
0.91
|
|
56
|
Molecular and functional genetics of hepatocellular carcinoma.
|
Front Biosci (Schol Ed)
|
2010
|
0.90
|
|
57
|
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
|
PLoS One
|
2013
|
0.89
|
|
58
|
Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
|
Liver Int
|
2009
|
0.88
|
|
59
|
Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin.
|
Liver Transpl
|
2004
|
0.88
|
|
60
|
TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma.
|
Front Med
|
2015
|
0.87
|
|
61
|
A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10.
|
J Immunol
|
2007
|
0.86
|
|
62
|
Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers.
|
Liver Cancer
|
2013
|
0.86
|
|
63
|
N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H.
|
J Cell Sci
|
2010
|
0.86
|
|
64
|
Role and significance of focal adhesion proteins in hepatocellular carcinoma.
|
J Gastroenterol Hepatol
|
2009
|
0.86
|
|
65
|
Ketamine-induced cholangiopathy: a case report.
|
Am J Gastroenterol
|
2011
|
0.84
|
|
66
|
Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts.
|
Liver Transpl
|
2003
|
0.84
|
|
67
|
Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma.
|
PLoS One
|
2011
|
0.84
|
|
68
|
Intraoperative iatrogenic rupture of hepatocellular carcinoma.
|
World J Surg
|
2002
|
0.84
|
|
69
|
Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway.
|
Liver Int
|
2010
|
0.83
|
|
70
|
HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions.
|
Int J Cancer
|
2009
|
0.83
|
|
71
|
Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma.
|
Future Oncol
|
2012
|
0.81
|
|
72
|
The impact of hypoxia in hepatocellular carcinoma metastasis.
|
Front Med
|
2013
|
0.81
|
|
73
|
Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma.
|
Oncol Rep
|
2004
|
0.81
|
|
74
|
Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery.
|
PLoS One
|
2011
|
0.81
|
|
75
|
CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells.
|
PLoS One
|
2012
|
0.81
|
|
76
|
Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations.
|
Cancer Res
|
2008
|
0.81
|
|
77
|
Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins.
|
Front Med
|
2013
|
0.80
|
|
78
|
Cholangiocarcinoma in liver cirrhosis.
|
J Gastroenterol Hepatol
|
2003
|
0.80
|
|
79
|
Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer.
|
Cancer Res
|
2008
|
0.80
|
|
80
|
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.
|
Chin J Cancer Res
|
2011
|
0.80
|
|
81
|
Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells.
|
J Biomed Sci
|
2004
|
0.80
|
|
82
|
Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center.
|
Arch Surg
|
2004
|
0.80
|
|
83
|
MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility.
|
Front Med
|
2015
|
0.79
|
|
84
|
PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis.
|
Nat Commun
|
2013
|
0.79
|
|
85
|
Reversal of protein-losing enteropathy by liver transplantation.
|
J Clin Gastroenterol
|
2003
|
0.78
|
|
86
|
Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK.
|
BMC Complement Altern Med
|
2014
|
0.78
|
|
87
|
The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
|
Hepatology
|
2012
|
0.78
|
|
88
|
Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
|
PLoS One
|
2011
|
0.76
|
|
89
|
Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.
|
J Biol Chem
|
2012
|
0.76
|
|
90
|
Hepatic stress gene expression and ultrastructural features under intermittent Pringle manoeuvre.
|
Hepatobiliary Pancreat Dis Int
|
2002
|
0.75
|
|
91
|
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma.
|
J Clin Invest
|
2017
|
0.75
|
|
92
|
Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma.
|
J Pathol
|
2014
|
0.75
|